Table A1. LVEF Measurements and CV-Related Medication Use for Participants With LVEF Decline ≥ 10% From Baseline to LTF and Long-Term LVEF < 50%

<table>
<thead>
<tr>
<th>Patient</th>
<th>Treatment*</th>
<th>LVEF Baseline</th>
<th>LVEF 18 Months</th>
<th>LVEF LTF</th>
<th>Use</th>
<th>CV Medication</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>77</td>
<td>62</td>
<td>48</td>
<td>Yes</td>
<td>Hypertension, angina, CHF</td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>60</td>
<td>56</td>
<td>49</td>
<td>Yes</td>
<td>Elevated lipids</td>
</tr>
<tr>
<td>3</td>
<td>1</td>
<td>60</td>
<td>57</td>
<td>43</td>
<td>No</td>
<td>NA</td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>62</td>
<td>60</td>
<td>24</td>
<td>Yes</td>
<td>Hypertension, CHF, cardiomyopathy, atrial fibrillation</td>
</tr>
<tr>
<td>5</td>
<td>1</td>
<td>62</td>
<td>56</td>
<td>44</td>
<td>Yes</td>
<td>Diabetes</td>
</tr>
<tr>
<td>6</td>
<td>2</td>
<td>56</td>
<td>53</td>
<td>38</td>
<td>Yes</td>
<td>Hypertension, elevated lipids</td>
</tr>
<tr>
<td>7</td>
<td>2</td>
<td>67</td>
<td>57</td>
<td>44</td>
<td>Yes</td>
<td>Diabetes, elevated lipids</td>
</tr>
<tr>
<td>8</td>
<td>2</td>
<td>65</td>
<td>58</td>
<td>45</td>
<td>Yes</td>
<td>Hypertension, diabetes</td>
</tr>
<tr>
<td>9</td>
<td>2</td>
<td>66</td>
<td>59</td>
<td>48</td>
<td>No</td>
<td>NA</td>
</tr>
<tr>
<td>10</td>
<td>2</td>
<td>60</td>
<td>59</td>
<td>48</td>
<td>Yes</td>
<td>Diabetes</td>
</tr>
<tr>
<td>11</td>
<td>2</td>
<td>71</td>
<td>51</td>
<td>49</td>
<td>No</td>
<td>NA</td>
</tr>
<tr>
<td>12</td>
<td>2</td>
<td>61</td>
<td>47</td>
<td>47</td>
<td>Yes</td>
<td>Hypertension, elevated lipids</td>
</tr>
<tr>
<td>13</td>
<td>2</td>
<td>56</td>
<td>45</td>
<td>42</td>
<td>No</td>
<td>NA</td>
</tr>
<tr>
<td>14</td>
<td>2</td>
<td>70</td>
<td>52</td>
<td>34</td>
<td>Yes</td>
<td>Hypertension, CHF, elevated lipids</td>
</tr>
<tr>
<td>15</td>
<td>2</td>
<td>66</td>
<td>61</td>
<td>48</td>
<td>No</td>
<td>NA</td>
</tr>
</tbody>
</table>

Abbreviations: CHF, congestive heart failure; CV, cardiovascular; LTF, long-term followup. LVEF, left ventricular ejection fraction; NA, not applicable. *Treatment 1, doxorubicin and cyclophosphamide plus paclitaxel; treatment 2, doxorubicin and cyclophosphamide plus paclitaxel and trastuzumab.